Alcon Touts Positive Data for Vivity IOL Registry Study

Alcon has revealed final data from its Vivity registry study, which monitored real-world patient experiences for up to a year after cataract surgery. Patients were implanted with either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL).
 
Alcon said data from over 900 cataract patients demonstrated sustained clinical performance, high patient satisfaction, and reduced dependence upon glasses. Evidence also suggested that AcrySof IQ Vivity can be used successfully in a wide range of patients.
 
“Since its introduction, AcrySof IQ Vivity has been a disruptive technology—and an innovation we are very proud of as a company. Vivity is a first-of-its kind, non-diffractive extended depth of focus IOL built with our proprietary X-WAVE technology, which stretches and shifts light without splitting it,” Sunil Vasanth, VP, Europe Surgical Franchise, Alcon, told the press. “Our real-world registry data gives surgeons the confidence that Vivity’s performance is sustained over time. This data is also important as it includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy.”
 
The registry study was conducted across 41 sites from eight countries: Australia, Belgium, Germany, New Zealand, the Netherlands, Portugal, Spain, and the U.K.
 
According to Alcon’s data, three-quarters of patients reported no difficulty with sight for activities in daily life. 92% of patients reported satisfaction with sight, and over 91% reported no halos, glares, or starbursts—common visual disturbances associated with splitting the light in a diffractive IOL.
 
The company observed “excellent” binocular distance and intermediate uncorrected visual acuity, with mean Snellen visual acuity values of 20/20 and 20/25, respectively. Over 78% and 88% of patients reported no longer needing glasses to see at arm’s length and far away, respectively.
 
Alcon also released favorable results of its Alcon Eye On Cataract Survey a few weeks ago.